diabetes type 2  

     

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

alpha-glucosidase inhibitors

not classified
Study 541 -
Study 656, 1994 -
Campbell et al, 1998 -
Bachmann et al, 1998 -
Koyasu, 2010 -
Chiasson et al, 1994placeboLow risk of bias -
Hasche et al, 1999placeboLow risk of bias -
Josse et al, 2003placeboLow risk of bias -
Halimi, 2000errorplacebo (add on to met)Low risk of bias -
Rosenstock, 1998errorplacebo (add on to met)Low risk of bias negative
Van Gaal, 2001miglitolplacebo (add on to met)Low risk of bias negative

angiotensin renin system blockade

not classified
HOPE (diabetic subgroup), 2000ACE inhibitorsplaceboLow risk of bias suggesting
ADVANCE, 2007perindopril and indapamideplaceboNCT00145925Low risk of bias -
NAGOYA HEART, 2011valsartanamlodipineNCT00129233Risk of bias negative
STOP-2 (ACEI vs CCB) (diabetic subgroup), 2000ACE inhibitorcalcium-channel blockerExploratory negative
STOP-2 (ACEI, diabetic subgroup), 2000ACE inhibitordiuretic or beta-blockerExploratory negative
captopril
UKPDS 38, 1998captopril or atenololcontrolExploratory suggesting
UKPDS 39, 1998captoprilatenololExploratory negative
CAPP (diabetic subgroup), 1999captoprildiuretic and/or beta-blockersExploratory suggesting
irbesartan
IPDM (150mg), 2001irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs pbo), 2001irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs amlodipine), 2001irbesartanamlodipineLow risk of bias suggesting
lisinopril
ALLHAT (lisi vs chlor, diabetic subgroup), 2002lisinoprilchlorthalidoneLow risk of bias negative
losartan
RENAAL, 2001losartanplaceboLow risk of bias suggesting
olmesartan
ROADMAP, 2010olmesartanplaceboNCT00185159Low risk of bias suggesting
ORIENTolmesartanplaceboNCT00141453Low risk of bias negative

angiotensin-receptor blockers

not classified
ADVANCE, 2007perindopril and indapamideplaceboNCT00145925Low risk of bias -
NAGOYA HEART, 2011valsartanamlodipineNCT00129233Risk of bias negative
irbesartan
IPDM (150mg), 2001irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs amlodipine), 2001irbesartanamlodipineLow risk of bias suggesting
losartan
RENAAL, 2001losartanplaceboLow risk of bias suggesting
olmesartan
ROADMAP, 2010olmesartanplaceboNCT00185159Low risk of bias suggesting
ORIENTolmesartanplaceboNCT00141453Low risk of bias negative

anti hypertensive agents

not classified
INVEST (subgroup), 2003verapamilcontrolnegative
HOPE (diabetic subgroup), 2000ACE inhibitorsplaceboLow risk of bias suggesting
SCAT (diabetic subgroup), 2000enalaprilplaceboLow risk of bias -
SOLVD (subgroup), 1996enalaprilplaceboLow risk of bias negative
ACTION, 1998nifedipineplaceboLow risk of bias negative
PROGRESS (diabetic subgroup), 2001perindoprilplaceboLow risk of bias suggesting
EUROPA (PERSUADE substudy), 2005perindoprilplaceboExploratory negative
ADVANCE, 2007perindopril and indapamideplaceboNCT00145925Low risk of bias -
ADVANCE, 2007perindopril and indapamideplaceboNCT00145925Low risk of bias suggesting
PROFESS, 2008telmisartanplaceboLow risk of bias -
ACCORD (blood pressure), 2010intensiveusualNCT00000620Risk of bias suggesting
HOT <=80 (diabetic subgroup), 1998intensiveusualExploratory suggesting
ABCD normotensives, 1993intensiveusualExploratory suggesting
JMIC-B (diabetic subgroup), 2004nifedipineACE inhibitorExploratory negative
NAGOYA HEART, 2011valsartanamlodipineNCT00129233Risk of bias negative
ASCOT (subgroup), 2008amlodipineatenololLow risk of bias suggesting
ACCOMPLISH (diabetic subgroup), 2010benazepril + amlodipinebenazepril + hydrochlorothiazideNCT00170950Low risk of bias suggesting
STOP-2 (ACEI vs CCB) (diabetic subgroup), 2000ACE inhibitorcalcium-channel blockerExploratory negative
NORDIL (diabetic subgroup), 2000diltiazemdiuretic and/or beta-blockerExploratory negative
STOP-2 (ACEI, diabetic subgroup), 2000ACE inhibitordiuretic or beta-blockerExploratory negative
STOP-2 (CCB, diabetic subgroup), 2000calcium-channel blockerdiuretic or beta-blockerExploratory negative
DETAIL, 2004temisartanenalaprilLow risk of bias negative
GEMINI, 2004carvedilolmetoprololExploratory negative
amlodipine
IDNT (amlodipine vs PBO), 2001amlodipineplaceboLow risk of bias negative
ALLHAT (amlodipine vs chlor, diabetic subgroup), 2002amlodipinechlorthalidoneLow risk of bias negative
FACET, 1997amlodipinefosinoprilRisk of bias suggesting
candesartan
SCOPE (diabetic subgroup), 2003candesartancontrolLow risk of bias negative
captopril
UKPDS 38, 1998captopril or atenololcontrolExploratory suggesting
UKPDS 39, 1998captoprilatenololExploratory negative
CAPP (diabetic subgroup), 1999captoprildiuretic and/or beta-blockersExploratory suggesting
chlorthalidone
SHEP (diabetic subgroup), 1996chlorthalidoneplaceboLow risk of bias suggesting
intensive blood pressure lowering strategies
ABCD target (H) , 2000more intensive blood pressure lowering strategieless intensive blood pressure lowering strategie type 2 diabetes suggesting
ABCD target (N) , 2002more intensive blood pressure lowering strategieless intensive blood pressure lowering strategie type 2 diabetes suggesting
irbesartan
IPDM (150mg), 2001irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs pbo), 2001irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs amlodipine), 2001irbesartanamlodipineLow risk of bias suggesting
lisinopril
ALLHAT (lisi vs chlor, diabetic subgroup), 2002lisinoprilchlorthalidoneLow risk of bias negative
losartan
RENAAL, 2001losartanplaceboLow risk of bias suggesting
LIFE (diabetic subgroup), 2002losartanatenololLow risk of bias suggesting
metoprolol
MERIT-HF, 2005metoprololplaceboLow risk of bias negative
nidrendipine
Syst-Eur (diabetic subgroup), 1999nitrendipineplaceboLow risk of bias suggesting
nifedipine
INSIGHT (diabetic subgroup), 2000nifedipinecoamilozideLow risk of bias negative
nisoldipine
ABCD (hypertension), 1998nisoldipineenalaprilLow risk of bias suggesting
olmesartan
ROADMAP, 2010olmesartanplaceboNCT00185159Low risk of bias suggesting
ORIENTolmesartanplaceboNCT00141453Low risk of bias negative
ramipril
DIABHYCAR, 2004ramiprilplaceboLow risk of bias negative
DREAM, 2008ramiprilplacebonegative

antidiabetic drugs

not classified
Cefalu, 1998 -
Hermann, 1994 -
Charpentier, 2001 -
YSRE0001repaglinide???NCT00336310Low risk of bias -
UGDPinsulincontrolsuggesting
UKPDS 33insulincontrolnegative
Derosa , 2009nateglinideglibenclamide (add on MET)Low risk of bias -
AGEE-3783repaglinidegliclazideNCT01022762 -
PRESERVE-betanateglinideglyburide (add on MET) -
AGEE-1524repaglinide + insulininsulinNCT00799448 -
AGEE-3020repaglinide + insulininsulin -
GLORIAmitiglinide+vogliboseinsulin glargineNCT00663884 -
Horton DOUBLON, 2000nateglinide + metforminmetformin -
ReMetrepaglinideMetforminNCT00118950Low risk of bias -
AGEE-1411repaglinide + metforminmetforminNCT01465152 -
ReformrepaglinideMetformin (add on insulin)NCT00118963Low risk of bias -
CDJN608AUS13 nateglinideplacebo -
CDJN608AUS13 nateglinideplacebo -
CDJN608A ES03nateglinideplacebo -
NAVIGATORnateglinideplacebo -
Schwarz , 2008nateglinideplaceboLow risk of bias -
Schwarz (study 2), 2008nateglinideplaceboLow risk of bias -
Buse, 2011exenatide 20µg/dplacebo (add on insulin)NCT00765817Low risk of bias negative
Dashora , 2007nateglinideplacebo (add on insulin)Low risk of bias -
Juurinen , 2009nateglinideplacebo (add on insulin+MET)Low risk of bias -
Fineman, 2003exenatide other dosesplacebo (add on MER+/-SU)Exploratory -
DeFronzo 10µg/d, 2005exenatide 10µg/dplacebo (add on MET)NCT00039013Low risk of bias negative
DeFronzo 20µg/d, 2005exenatide 20µg/dplacebo (add on MET)NCT00039013Low risk of bias suggesting
Kim, 2007exenatide weeklyplacebo (add on MET)NCT00103935Exploratory negative
NCT01037842mitiglinideplacebo (add on MET)NCT01037842Low risk of bias -
EX-1510-CT-003mitiglinideplacebo (add on MET)NCT00519142Low risk of bias -
Gao, 2009exenatide 20µg/dplacebo (add on MET+/-SU)NCT00324363Low risk of bias suggesting
NCT00402909nateglinideplacebo (add on standard treatment)NCT00402909Low risk of bias -
Buse 10µg/d, 2004exenatide 10µg/dplacebo (add on SU)NCT00039026negative
Buse 20µg/d, 2004exenatide 20µg/dplacebo (add on SU) -
Kadowaki (trial 8683), 2009exenatide 10µg/dplacebo (add on SU+/-MET/TZD)Exploratory negative
Kendall 10µg/d, 2005exenatide 10µg/dplacebo (add on SU+MET)NCT00035984Low risk of bias negative
Kendall 20µg/d, 2005exenatide 20µg/dplacebo (add on SU+MET)NCT00035984Low risk of bias suggesting
026-CL-004 ongoing nateglinideplacebo (add on TZD)NCT00189774Low risk of bias ongoing
Zinman 20µg/j, 2007exenatide 20µg/dplacebo (add on TZD+/-MET)NCT00099320Low risk of bias suggesting
Zinman 20µg/j A MODIFIER, 2007exenatide 20µg/dplacebo (add on TZD+/-MET)Low risk of bias -
AGEE-1411metformin + repagliniderepaglinideNCT01465152 -
Rosenstock , 2004nategliniderepaglinide -
AGEE-3705repaglinide + metforminrepaglinideNCT00819741 -
AGEE-3018repaglinide + metforminrepaglinide -
Raskin , 2009repaglinide + metforminrosiglitazone + metforminNCT00399711 -
AGEE-3017repaglinide + metforminSU or METNCT00568984 -
phase 2 exenatide once monthlyexenatide once monthlyweekly exenatide -
Exenatide Trial 10749exenatide before lunch and dinnerexenatide before breakfast and dinnerRisk of bias -
Heine, 2005exenatide 20µg/dinsulin (add on SU+MET)negative
Davis, 2007exenatide 20µg/dinsulin (add on SU/MET)NCT00099333Risk of bias negative
Barnett, 2007exenatide 20µg/dinsulin (add on SU/MET)NCT00099619Exploratory suggesting
Nauck, 2007exenatide 20µg/dinsulin BIAsp twice daily add on SU+METNCT00082407Risk of bias negative
DURATION-3 (Diamant), 2010exenatide weeklyinsulin glargineNCT00641056Risk of bias suggesting
Trial 8078exenatide other dosesinsulin glargine (add on MET/SU) -
albiglutide
Rosenstock (30 mg weekly), 2009albiglutide weeklyplacebo (add on MET)NCT00518115Exploratory suggesting
alogliptin
Nauck, 2009alogliptinplacebo (add on MET)NCT00286442Low risk of bias negative
dapagliflozin
Bailey (MB102014), 2010dapagliflozinplacebo (add on MET)NCT00528879Low risk of bias -
glimeripide
Study 201 (Goldberg), 1996glimepirideplaceboLow risk of bias -
Schade, 1998glimepirideplaceboLow risk of bias -
Rosenstock, 1996glimepirideplaceboLow risk of bias -
Luis Bautista, 2003glimepirideplaceboLow risk of bias -
Kaneko, 1993glimepirideplacebo -
Study 202glimepirideplacebo -
Riddle, 1994glimepirideplacebo (add on insulin) -
Charpentier, 2001glimepirideplacebo (add on MET)Low risk of bias negative
Draeger, 1996glimepirideglibenclamideLow risk of bias -
Protocol 311glimepirideglibenclamide -
Charpentier (301F)glimepiridegliclazide -
Inukai, 2005glimepiridegliclazide or glibenclamide -
Sonnenberg, 1997glimepiride odglimepiride bid -
Clark (301), 1997glimepirideglipizide -
Dills, 1996glimepirideglyburideLow risk of bias -
glipizide
Goldsteinglipizidecontrol (add on MET) -
Rosenstock, 1993glipizideglyburide -
Birkeland, 1994glipizideglyburide -
Birkeland, 1994glipizideglyburideLow risk of bias -
Simonson, 1997glipizideplaceboLow risk of bias -
Testa, 1998glipizideplacebo -
glyburide
Hermann, 1991glibenclamidec (add on MET) -
DeFronzo, 1995glyburidec (add on MET)Low risk of bias -
Erle, 1999glyburidec (add on MET) -
Marre (ass), 2002glibenclamidecontrol (add on MET)Low risk of bias -
Tosi, 2003glibenclamidecontrol (add on MET)Low risk of bias -
Blonde, 2002glyburidecontrol (add on MET)Low risk of bias -
Garber, 2003glyburidecontrol (add on MET) -
Garber, 2002glyburideplaceboLow risk of bias -
Vray, 1995glyburideplaceboLow risk of bias -
linagliptin
Gallwitz, 2012linagliptinglimepiride (add on MET)NCT00622284Low risk of bias -
linagliptin 1218.62 ongoing linagliptin low doselinagliptinNCT01012037Low risk of bias ongoing
OwenslinagliptinMetformin + sulfonylureaNCT00602472 -
Del PratolinagliptinplaceboNCT00621140Low risk of bias -
linagliptin 1218.65 ongoing linagliptinplacebo (add on MET)NCT01215097Low risk of bias ongoing
linagliptin 1218.61 ongoing linagliptinplacebo (add on MET+TZD)NCT00996658 ongoing
Lewin, 2010linagliptinplacebo (add on SU)NCT00819091Low risk of bias -
linagliptin 1264.3 ongoing linagliptin + pioglitazonepioglitazoneNCT01183013 ongoing
liraglutide
NN2211-1799 ongoing liraglutide other dosesplaceboNCT00620282Low risk of bias ongoing
LEAD-2 (Nauck) (1.8mg vs placebo), 2009liraglutide 1.8mgplacebo (add on MET)NCT00318461Low risk of bias suggesting
LEAD-1 SU (1.2 mg vs placebo), 2009liraglutide 1.2mgplacebo (add on SU)NCT00318422Low risk of bias suggesting
LEAD-1 SU (1.8 mg vs placebo), 2009liraglutide 1.8mgplacebo (add on SU)NCT00318422Low risk of bias suggesting
NN2211-1701 ongoing liraglutide other dosesplacebo (add on SU)NCT00395746Low risk of bias ongoing
LEAD-5 (vs placebo), 2009liraglutide 1.8mgplacebo (add on SU+MET)NCT00331851Low risk of bias suggesting
LEAD-4 (1.2mg), 2009liraglutide 1.2mgplacebo (add on TZD+MET)NCT00333151Low risk of bias suggesting
LEAD-4 (1.8mg), 2009liraglutide 1.8mgplacebo (add on TZD+MET)NCT00333151Low risk of bias suggesting
MK-0431-403 ongoing liraglutide other dosessitagliptin (add on MET)NCT01296412 ongoing
LEAD-6, 2009liraglutide 1.8mgexenatide on top MET/SU/MET+SUNCT00518882Risk of bias suggesting
Seino, 2010liraglutide other dosesglibenclamideNCT00393718Low risk of bias negative
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009liraglutide 1.8mgglimepiride (add on MET)NCT00318461Low risk of bias negative
EAGLE ongoing liraglutide other dosesinsulin glargineNCT01117350 ongoing
LEAD-5 (vs Glargine), 2009liraglutide 1.8mginsulin glargine (add on SU+MET)NCT00331851Risk of bias negative
LEAD-1 SU (1.8 vs rosiglitazone), 2009liraglutide other dosesrosiglitazone (add on SU)NCT00318422Low risk of bias suggesting
Pratley 1.2mg, 2010liraglutide 1.2mgsitagliptinNCT00700817Risk of bias suggesting